Lv3
220 积分 2025-05-13 加入
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
1个月前
已完结
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study
1个月前
已完结
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
2个月前
已完结
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study
2个月前
已完结
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study
2个月前
已完结
Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas
3个月前
已完结
Post-marketing safety of Adagrasib: a disproportionality analysis based on the FAERS database
4个月前
已完结
Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event reporting System (FAERS) database: A real-world pharmacovigilance study
4个月前
已完结
Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors
4个月前
已完结
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial
4个月前
已完结
皖公网安备34019202002308
